Alcon Net Common Equity Issued/Repurchased 2019-2024 | ALC
Alcon annual/quarterly net common equity issued/repurchased history and growth rate from 2019 to 2024. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
- Alcon net common equity issued/repurchased for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Alcon net common equity issued/repurchased for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Alcon annual net common equity issued/repurchased for 2024 was $0B, a 0% decline from 2023.
- Alcon annual net common equity issued/repurchased for 2023 was $0B, a 0% decline from 2022.
- Alcon annual net common equity issued/repurchased for 2022 was $0B, a 0% decline from 2021.
| Alcon Annual Net Common Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $48.486B | $9.911B |
| Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. | |||